Source :
https://www.prnewswire.com/news-releases/fda-approves-sarclisa-isatuximab-irfc-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma-301260109.htmlPARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy.
An expanded indication for a cd38 antibody, which are in key class of medications in the treatment of myeloma ...